Remyelination varies between and within lesions in multiple sclerosis following bexarotene

In multiple sclerosis chronic demyelination is associated with axonal loss, and ultimately contributes to irreversible progressive disability. Enhancing remyelination may slow, or even reverse, disability. We recently trialled bexarotene versus placebo in 49 people with multiple sclerosis. While the...

Descripción completa

Detalles Bibliográficos
Autores: Brown, William, Prados Carrasco, Ferran, Altmann, Daniel, Kanber, Baris, Stutters, Jonathan, Cunniffe, Nick, Jones, Joanne, Georgieva, Zoya, Needham, Edward, Daruwalla, Cyrus, Gandini Wheeler-Kingshott, Claudia A.M., Connick, Peter, Chandran, Siddharthan, Franklin, Robin, MacManus, David, Samson, Rebecca, Coles, Alasdair, Chard, Declan
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universitat Oberta de Catalunya (UOC)
Repositorio:O2, repositorio institucional de la UOC
OAI Identifier:oai:openaccess.uoc.edu:10609/147057
Acceso en línea:https://hdl.handle.net/10609/147057
http://doi.org/10.1002/acn3.51662
Access Level:acceso abierto
Palabra clave:multiple sclerosis
esclerosi múltiple
esclerosis múltiple
Descripción
Sumario:In multiple sclerosis chronic demyelination is associated with axonal loss, and ultimately contributes to irreversible progressive disability. Enhancing remyelination may slow, or even reverse, disability. We recently trialled bexarotene versus placebo in 49 people with multiple sclerosis. While the primary MRI outcome was negative, there was converging neurophysiological and MRI evidence of efficacy. Multiple factors influence lesion remyelination. In this study we undertook a systematic exploratory analysis to determine whether treatment response – measured by change in magnetisation transfer ratio – is influenced by location (tissue type and proximity to CSF) or the degree of abnormality (using baseline magnetisation transfer ratio and T1 values).

Similares en LA Referencia